Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Quon, H ^b   Abdulkarim, Bassam ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; COMPARATIVE STUDY; DATA ANALYSIS; DISEASE FREE SURVIVAL; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HETEROZYGOSITY; HUMAN; INFORMATION PROCESSING; LUNG INFECTION; NEUROLOGIC DISEASE; NEUTROPENIA; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SALVAGE THERAPY;

EID: 44949247296     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007104     Document Type: Review

References (11)

1. Cairncross 2006 {published data only} Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology 2006;24(18):2707-14.
2. van den Bent 2006 {published data only} van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology 2006;24(18):2715-22.
3. Cairncross 1994 Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1994;12(10):2013-21.
4. Cairncross 1998 Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute 1998;90(19):1473-79.
5. CBTRUS 2005 Central Brain Tumor Registry of the United States. Primary brain tumors in the United States statistical report ,1998-2002 (Years Data Collected). http://www.cbtrus.org/reports/reports.html 2005.
6. Guyatt 2002 Guyatt G, Drummond R, editors. Users' guides to the medical literature: essentials of evidence-based clinical practice. Chicago, IL: AMA Press, 2002.
7. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated eptember 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
8. Hoang-Xuan 2004 Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. Journal of Clinical Oncology 2004;22(15):3133-38.
9. Smith 2000 Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Journal of Clinical Oncology 2000;18(3):636-45.
10. Stupp 2005 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352:987-96.
11. van den Bent 2003 van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-84.